Homocysteine et maladie thrombo-embolique veineuse. [Homocysteine and venous thromboembolism]

Détails

ID Serval
serval:BIB_B7BAF7878A78
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Homocysteine et maladie thrombo-embolique veineuse. [Homocysteine and venous thromboembolism]
Périodique
Schweizerische Medizinische Wochenschrift
Auteur⸱e⸱s
Monnerat  C., Hayoz  D.
ISSN
0036-7672 (Print)
Statut éditorial
Publié
Date de publication
09/1997
Volume
127
Numéro
36
Pages
1489-96
Notes
English Abstract
Journal Article
Review --- Old month value: Sep 6
Résumé
Congenital homocysteinuria is a rare inherited metabolic disorder with early onset atherosclerosis and arterial and venous trombosis. Moderate hyperhomocysteinemia is more frequently encountered and is recognized as an independent cardiovascular risk factor. Several case-control studies demonstrate an association between venous thromboembolism and moderate hyperhomocysteinemia. A patient with moderate hyperhomocysteinemia has a 2-3 relative risk of developing an episode of venous thromboembolism. The occurrence of mild hyperhomocysteinemia in heterozygotes for the mutation of Leiden factor V involves a 10-fold increase in the risk of venous thromboembolism. The biochemical mechanism by which homocysteine may promote thrombosis is not fully recognized. Homocysteine inhibits the expression of thrombomodulin, the thrombin cofactor responsible for protein C activation, and inhibits antithrombin-III binding. Treatment with folic acid reduces the plasma level of homocysteinemia, but no study has demonstrated its efficacy in reducing the incidence of venous thromboembolism or atherosclerosis. Hyperhomocysteinemia should be included in the screening of abnormalities of hemostasis and thrombosis in patients with idiopathic thromboembolism, and mild hyperhomocysteinemia may justify a trial of folic acid.
Mots-clé
Adolescent Adult Amino Acid Metabolism, Inborn Errors/blood/drug therapy/*genetics Female Folic Acid/therapeutic use Heterozygote Detection Homocysteine/*blood Humans Male Middle Aged Risk Thromboembolism/blood/drug therapy/*genetics Thrombophlebitis/blood/drug therapy/*genetics
Pubmed
Web of science
Création de la notice
17/01/2008 16:38
Dernière modification de la notice
20/08/2019 15:25
Données d'usage